Achieve Life Sciences (NASDAQ:ACHV – Get Rating) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.07), MarketWatch Earnings reports. During the same quarter in the prior year, the company posted ($1.11) earnings per share.
NASDAQ ACHV traded up $0.16 during trading on Friday, reaching $6.89. The company’s stock had a trading volume of 30 shares, compared to its average volume of 38,581. The stock has a market capitalization of $65.13 million, a PE ratio of -1.45 and a beta of 1.19. The firm has a fifty day moving average of $7.60 and a 200 day moving average of $7.84. Achieve Life Sciences has a one year low of $6.24 and a one year high of $12.95.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Achieve Life Sciences by 455.6% in the 4th quarter. BlackRock Inc. now owns 15,207 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 12,470 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Achieve Life Sciences in the 4th quarter worth about $149,000. LPL Financial LLC boosted its holdings in shares of Achieve Life Sciences by 4.7% in the 3rd quarter. LPL Financial LLC now owns 72,000 shares of the biopharmaceutical company’s stock worth $612,000 after purchasing an additional 3,200 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Achieve Life Sciences by 51.0% in the 3rd quarter. Geode Capital Management LLC now owns 85,554 shares of the biopharmaceutical company’s stock worth $727,000 after purchasing an additional 28,885 shares in the last quarter. Finally, Morgan Stanley boosted its holdings in shares of Achieve Life Sciences by 59.0% in the 2nd quarter. Morgan Stanley now owns 139,200 shares of the biopharmaceutical company’s stock worth $1,250,000 after purchasing an additional 51,654 shares in the last quarter. Institutional investors and hedge funds own 35.86% of the company’s stock.
About Achieve Life Sciences (Get Rating)
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Achieve Life Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Achieve Life Sciences wasn’t on the list.
While Achieve Life Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.